GSK strengthened its oncology pipeline with two developments: the US Food and Drug Administration granted orphan drug designation to risvutatug rezetecan for small-cell lung cancer, and the company entered a cancer drug discovery collaboration with Oxford BioTherapeutics.
Risvutatug rezetecan, an early-stage B7-H3-targeted antibody-drug conjugate licensed from Hansoh Pharma in 2023, received its fifth regulatory designation. The FDA decision was based on data from the phase 1 Artemis-001 trial, in which patients with extensive-stage SCLC showed durable tumor responses. GSK noted that patients with extensive-stage SCLC face high relapse risk and low survival rates.
GSK is also developing risvutatug rezetecan for prostate and colorectal cancers.
Under a multi-year, multi-target agreement, GSK will collaborate with UK-based Oxford BioTherapeutics to discover potential first-in-class oncology therapies using Oxford’s OGAP-Verify proteomics platform. Identified targets will undergo joint validation before GSK assumes responsibility for further research, development and commercialization.
The deal includes an undisclosed upfront payment to Oxford BioTherapeutics, plus downstream milestone payments and royalties on net sales.
“At GSK, we are committed to discovering, developing and delivering novel medicines to patients in need. Our collaboration with Oxford BioTherapeutics enhances our in-house capabilities by integrating a best-in-class proteomics platform for oncology target identification, enabling us to work together to deliver impactful solutions for patients,” said Chris Austin, GSK senior vice president of research technologies.
GSK shares were marginally in the red in Wednesday midmorning trade.
Leave a Reply